Latest news with #MereoBioPharma
Yahoo
11-08-2025
- Business
- Yahoo
Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143
Mereo BioPharma Group plc (NASDAQ:MREO) is one of the . On July 9, Mereo BioPharma Group, along with Ultragenyx Pharmaceutical Inc., announced progress in the Phase 3 Orbit study testing UX143 for osteogenesis imperfecta. The study is moving toward a final analysis expected around the end of the year. Management noted that the Data Monitoring Committee reviewed the data and found UX143 to have an acceptable safety profile, giving them a go-ahead for the final analysis. Moreover, management also remains confident that increasing UX143 increases bone mass, leading to stronger bones, fewer fractures, and better physical abilities. A laboratory team in white coats working and testing new biopharmaceuticals. Ultragenyx's CEO, Emil D. Kakkis, noted that while they had hoped to close the trial earlier, they are eager to see complete results from the Orbit and Cosmic studies later this year. Mereo BioPharma Group plc (NASDAQ:MREO) is a biopharmaceutical company that develops medicines for rare diseases and cancer. The company is working on treatments like Setrusumab for brittle bone disease and alvelestat for severe lung disease. While we acknowledge the potential of MREO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-07-2025
- Business
- Yahoo
Exploring Three High Growth Tech Stocks In The US Market
Over the last 7 days, the United States market has risen 2.7% and is up 13% over the last 12 months, with earnings forecasted to grow by 15% annually. In this environment of robust growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in an ever-evolving landscape. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 24.99% 39.09% ★★★★★★ Mereo BioPharma Group 53.64% 66.60% ★★★★★★ Ardelyx 21.03% 60.42% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ Legend Biotech 26.68% 57.96% ★★★★★★ AVITA Medical 27.42% 61.05% ★★★★★★ Alnylam Pharmaceuticals 23.69% 60.42% ★★★★★★ Alkami Technology 20.53% 76.67% ★★★★★★ Ascendis Pharma 35.07% 59.92% ★★★★★★ Lumentum Holdings 22.99% 103.97% ★★★★★★ Click here to see the full list of 226 stocks from our US High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases globally, with a market cap of approximately $4.20 billion. Operations: ADMA focuses on developing and marketing plasma-derived biologics, primarily generating revenue from its Biomanufacturing segment, which accounts for $449.41 million, while its Plasma Collection Centers contribute $9.83 million. ADMA Biologics, having recently become profitable, exhibits a promising trajectory with its earnings expected to surge by 21.6% annually. This growth outpaces the broader US market's forecast of 14.7%. The firm's commitment to innovation is underscored by a recent FDA approval for a production process that boosts yields by 20%, significantly enhancing operational efficiency. Moreover, ADMA has initiated a robust share repurchase program valued at $500 million, reflecting confidence in its financial health and future prospects. These strategic moves, coupled with revenue projections rising to over $625 million by 2026, position ADMA well within the biotech sector's competitive landscape. Click here and access our complete health analysis report to understand the dynamics of ADMA Biologics. Evaluate ADMA Biologics' historical performance by accessing our past performance report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on providing therapies for autoimmune diseases with significant unmet needs and has a market cap of $1.08 billion. Operations: Aurinia Pharmaceuticals generates revenue primarily through the research, development, and commercialization of therapeutic drugs, amounting to $247.30 million. Aurinia Pharmaceuticals has recently demonstrated a robust growth trajectory, with revenue forecasted to grow at 12.2% annually, outpacing the US market's average of 8.8%. This growth is complemented by an impressive expected annual earnings increase of 25.8%, signaling strong operational efficiency and market confidence. The company's strategic focus on R&D is evident from its significant investment, which has facilitated innovative treatments in lupus nephritis—highlighted by recent successful clinical results that are poised to enhance patient outcomes and potentially alter therapeutic standards in the industry. Furthermore, Aurinia's proactive approach to capital management is underscored by its recent share repurchases totaling $108.28 million, reinforcing its commitment to shareholder value amidst expanding market presence. Navigate through the intricacies of Aurinia Pharmaceuticals with our comprehensive health report here. Learn about Aurinia Pharmaceuticals' historical performance. Simply Wall St Growth Rating: ★★★★☆☆ Overview: ADTRAN Holdings, Inc. is a company that offers networking and communications platforms, software, systems, and services across the United States, Germany, the United Kingdom, and internationally with a market capitalization of approximately $711.86 million. Operations: ADTRAN Holdings generates revenue primarily through its Network Solutions segment, contributing $759.91 million, and its Services & Support segment, which adds $184.38 million. ADTRAN Holdings is distinguishing itself in the high-growth tech landscape, particularly through its recent deployment of FSP 3000 open optical transport technology. This innovation not only enhances data center interconnect capabilities for Cegeka but also integrates advanced security features like ConnectGuard™ optical-layer encryption and real-time fiber monitoring, ensuring high-capacity and reliable data transport. Furthermore, ADTRAN's strategic focus on R&D is evidenced by its significant annual investment in this area, aligning with industry trends towards more secure and scalable network solutions. With a revenue growth rate of 10.8% per year outpacing the US market average of 8.8%, and an impressive forecasted earnings growth of 107.3% annually, ADTRAN is well-positioned to capitalize on increasing demands for sophisticated networking solutions in various sectors including telecom and defense. Click here to discover the nuances of ADTRAN Holdings with our detailed analytical health report. Gain insights into ADTRAN Holdings' past trends and performance with our Past report. Discover the full array of 226 US High Growth Tech and AI Stocks right here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ADMA AUPH and ADTN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-06-2025
- Business
- Yahoo
Exploring High Growth Tech Opportunities in US Markets
Over the last 7 days, the United States market has remained flat, yet it is up 11% over the past year with earnings forecasted to grow by 14% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and scalability potential to capitalize on these favorable conditions. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 26.38% 39.09% ★★★★★★ Mereo BioPharma Group 53.63% 66.57% ★★★★★★ Ardelyx 20.78% 59.46% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ AVITA Medical 27.36% 60.93% ★★★★★★ Blueprint Medicines 21.12% 60.77% ★★★★★★ Alnylam Pharmaceuticals 23.63% 60.71% ★★★★★★ Alkami Technology 20.54% 76.67% ★★★★★★ Ascendis Pharma 35.07% 59.92% ★★★★★★ Lumentum Holdings 22.99% 103.97% ★★★★★★ Click here to see the full list of 233 stocks from our US High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Palo Alto Networks, Inc. is a global provider of cybersecurity solutions with a market capitalization of $130.87 billion. Operations: The company generates revenue primarily from its Security Software & Services segment, amounting to $8.87 billion. Palo Alto Networks' strategic maneuvers, such as its recent partnership with Binary Defense, underscore its commitment to enhancing security operations through AI-driven platforms like Cortex XSIAM. This collaboration not only broadens the implementation and MDR services but also customizes support to fit diverse organizational needs, reflecting Palo Alto's adaptability in a high-stakes cybersecurity landscape. Moreover, their consistent R&D investment, which recently accounted for approximately 12.6% of their revenue, fuels innovations that keep them at the forefront of cybersecurity solutions. These efforts are pivotal as they navigate a competitive market where maintaining technological leadership is crucial for growth and client trust. Take a closer look at Palo Alto Networks' potential here in our health report. Assess Palo Alto Networks' past performance with our detailed historical performance reports. Simply Wall St Growth Rating: ★★★★★☆ Overview: Take-Two Interactive Software, Inc. is a global developer, publisher, and marketer of interactive entertainment solutions with a market cap of approximately $42.11 billion. Operations: The company generates revenue primarily through its publishing segment, which accounts for $5.63 billion. Take-Two Interactive Software has been actively expanding its financial and operational scope, as evidenced by recent strategic moves including a $1B public offering aimed at funding acquisitions and debt repayment. This aligns with their aggressive R&D investment strategy, crucial for fostering innovation in the highly competitive gaming sector. Despite reporting a net loss, Take-Two projects significant revenue growth ranging from $5.95B to $6.05B next fiscal year, underpinned by robust annualized revenue and earnings growth rates of 14.2% and 89.3%, respectively. These figures suggest a resilient adaptation to market demands and potential future profitability, positioning them well within the high-growth tech landscape despite current financial setbacks. Click here and access our complete health analysis report to understand the dynamics of Take-Two Interactive Software. Gain insights into Take-Two Interactive Software's historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Spotify Technology S.A., along with its subsidiaries, offers audio streaming subscription services globally and has a market capitalization of approximately $145.76 billion. Operations: Spotify generates revenue primarily through its Premium subscription service, which accounts for €14.34 billion, and its Ad-Supported segment, contributing €1.88 billion. Spotify Technology has demonstrated robust financial performance, with a notable increase in sales from EUR 3.64 billion to EUR 4.19 billion year-over-year and an uplift in net income to EUR 225 million. This growth is underpinned by a strategic emphasis on R&D, crucial for sustaining innovation and competitiveness in the dynamic tech landscape; indeed, Spotify's R&D expenses have consistently aligned with its revenue growth, ensuring continuous product evolution and market relevance. Moreover, the company's forward-looking revenue projection of $4.3 billion underscores its operational optimism and potential for sustained expansion within the tech sector. Click here to discover the nuances of Spotify Technology with our detailed analytical health report. Learn about Spotify Technology's historical performance. Explore the 233 names from our US High Growth Tech and AI Stocks screener here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PANW TTWO and SPOT. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-06-2025
- Business
- Yahoo
Exploring Three High Growth Tech Stocks In The US Market
In the last week, the United States market has been flat, yet it is up 9.9% over the past year with earnings projected to grow by 15% annually. In this context of steady growth and positive earnings forecasts, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health amidst these conditions. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 26.38% 39.09% ★★★★★★ Mereo BioPharma Group 53.63% 66.57% ★★★★★★ Ardelyx 21.03% 60.42% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ AVITA Medical 27.36% 60.93% ★★★★★★ Blueprint Medicines 21.12% 60.77% ★★★★★★ Alnylam Pharmaceuticals 23.63% 60.71% ★★★★★★ Alkami Technology 20.53% 76.67% ★★★★★★ Ascendis Pharma 35.07% 59.92% ★★★★★★ Lumentum Holdings 22.99% 103.97% ★★★★★★ Click here to see the full list of 229 stocks from our US High Growth Tech and AI Stocks screener. Let's uncover some gems from our specialized screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Tenable Holdings, Inc. offers cyber exposure management solutions across various global regions and has a market capitalization of approximately $4.01 billion. Operations: Tenable Holdings generates revenue primarily from its Security Software & Services segment, amounting to $923.20 million. The company operates across the Americas, Europe, the Middle East, Africa, the Asia Pacific, and Japan. Tenable Holdings, despite its current unprofitability, is strategically positioning itself for future profitability with significant leadership and product expansions. The company's recent appointment of experienced executives and the anticipated launch of an expanded Tenable One platform underscore a focused strategy on enhancing cybersecurity capabilities. Notably, Tenable's R&D expenditure has been robust, supporting its aggressive innovation trajectory. This commitment is reflected in its projected earnings growth of 61.1% annually and an ambitious revenue forecast aiming for $970 million to $980 million by year-end. Moreover, the repurchase of 1.6 million shares early this year highlights confidence in their strategic direction amidst a challenging competitive landscape. Click here to discover the nuances of Tenable Holdings with our detailed analytical health report. Gain insights into Tenable Holdings' past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Corning Incorporated operates in the optical communications, display technologies, environmental technologies, specialty materials, and life sciences sectors both in the United States and globally, with a market cap of approximately $43.23 billion. Operations: The company generates revenue primarily from optical communications ($5.08 billion) and display technologies ($3.91 billion), with additional contributions from specialty materials, life sciences, and Hemlock and emerging growth businesses. Corning's strategic collaborations and technological advancements underscore its potential in high-growth sectors like AI and mobile technologies. Recently, Corning partnered with Broadcom to enhance data center capacities with its optical components for a pioneering ethernet switch, reflecting significant strides in AI infrastructure efficiency. Additionally, the introduction of Gorilla Glass Ceramic 21 in Samsung's latest smartphone exemplifies Corning's influence on mobile durability innovations. These efforts are supported by robust R&D investments totaling $404 million last year, aimed at refining technologies that meet evolving digital demands. With a projected annual earnings growth of 27.9% and revenue increases expected at 9.6% per year, Corning is positioning itself as a key player in essential tech domains despite some financial setbacks like a notable one-off loss impacting recent results. Take a closer look at Corning's potential here in our health report. Evaluate Corning's historical performance by accessing our past performance report. Simply Wall St Growth Rating: ★★★★★☆ Overview: MNTN, Inc. is a performance TV software company that offers advertising services in the United States with a market capitalization of approximately $1.53 billion. Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $246.27 million. MNTN, recently public following a $187.2 million IPO, illustrates a dynamic shift in tech with its aggressive growth metrics and strategic legal structuring to bolster market presence. Despite current unprofitability, the company is on a trajectory with forecasted earnings growth at an impressive 74.5% annually, significantly outpacing the industry average. This performance is underpinned by substantial R&D investments aimed at pioneering innovations in software and AI technologies, ensuring MNTN remains competitive in a rapidly evolving sector. These efforts are complemented by recent regulatory updates and significant capital raised through equity offerings totaling nearly $700 million, positioning MNTN to capitalize on expanding market opportunities and enhance shareholder value. Click to explore a detailed breakdown of our findings in MNTN's health report. Review our historical performance report to gain insights into MNTN's's past performance. Explore the 229 names from our US High Growth Tech and AI Stocks screener here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include TENB GLW and MNTN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
22-05-2025
- Health
- Yahoo
Reproductive health startup raises $65M for infertility drugs
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. ReproNovo, a biotechnology company specializing in reproductive medicine, has raised $65 million to advance two drugs it thinks could help address fertility issues in men and women. The Switzerland-based firm plans to use the new funds to run Phase 2 clinical trials of the drugs. The first, called leflutrozole, is designed to treat infertility in men with low testosterone, while the second, nolasiban, will be studied in women with a gynecological disorder called adenomyosis and as an adjunctive therapy alongside assisted reproductive technologies. 'We are here to fill the critical gaps for patients in reproductive medicine and women's health,' Jean Maire Duvall, CEO and co-founder of ReproNovo, told BioPharma Dive. Founded in 2021, ReproNovo gained rights to the candidates through licensing deals with Mereo BioPharma and ObsEva, respectively. Leflutrozole is a small molecule that works by blocking an enzyme called aromatase. This effect, ReproNovo says, could help stabilize levels of testosterone and address male infertility. Some research has raised concerns about declines in male reproductive health, as fertility rates among women in the U.S. have also fallen. Although infertility impacts both men and women, the pressure and responsibility for solving the issue often falls on the woman. 'We'd like to offer an alternative where the male could be treated directly,' said Duvall. Nolasiban blocks oxytocin receptors, which ReproNovo sees as potentially helpful in managing adenomyosis, a condition where endometrial tissue grows in the uterine walls. Adenomyosis can cause similar symptoms as endometriosis, such as pelvic pain and heavy menstrual bleeding. The condition often occurs in women between the ages of 35 to 50. There are no drugs specifically approved to treat it. ReproNovo is also studying whether nolasiban can improve embryo implantation by reducing uterine contractility and enhancing blood flow amid embryo transfer during in vitro fertilization. While other treatments are available and in development to increase the chances of IVF success, none are approved to support embryo implantation specifically, the company said. The Series A funding round was led by Jeito Capital and co-led by AXA IM Alts and ReproNovo's founding investor M Ventures, the venture arm of Merck KGaA. Ysios Capital and Alsa Ventures also participated. Recommended Reading Women's health faces growing headwinds, despite jump in venture investment
